- Home
- MGTX vs VIR Comparison
MGTX vs VIR Comparison
Compare MGTX & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- VIR
- Stock Information
- Founded
- MGTX 2015
- VIR 2016
- Country
- MGTX United States
- VIR United States
- Employees
- MGTX N/A
- VIR N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- VIR Health Care
- Exchange
- MGTX Nasdaq
- VIR Nasdaq
- Market Cap
- MGTX 670.2M
- VIR 706.4M
- IPO Year
- MGTX N/A
- VIR 2019
- Fundamental
- Price
- MGTX $7.51
- VIR $5.02
- Analyst Decision
- MGTX Strong Buy
- VIR Strong Buy
- Analyst Count
- MGTX 2
- VIR 10
- Target Price
- MGTX $24.00
- VIR $26.80
- AVG Volume (30 Days)
- MGTX 325.1K
- VIR 1.5M
- Earning Date
- MGTX 08-14-2025
- VIR 10-30-2025
- Dividend Yield
- MGTX N/A
- VIR N/A
- EPS Growth
- MGTX N/A
- VIR N/A
- EPS
- MGTX N/A
- VIR N/A
- Revenue
- MGTX $37,917,000.00
- VIR $19,000,000.00
- Revenue This Year
- MGTX $145.67
- VIR N/A
- Revenue Next Year
- MGTX $167.61
- VIR $9.65
- P/E Ratio
- MGTX N/A
- VIR N/A
- Revenue Growth
- MGTX 366.84
- VIR N/A
- 52 Week Low
- MGTX $3.86
- VIR $4.16
- 52 Week High
- MGTX $8.98
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- MGTX 46.65
- VIR 50.66
- Support Level
- MGTX $7.39
- VIR $5.04
- Resistance Level
- MGTX $7.91
- VIR $5.39
- Average True Range (ATR)
- MGTX 0.36
- VIR 0.34
- MACD
- MGTX 0.01
- VIR 0.04
- Stochastic Oscillator
- MGTX 39.78
- VIR 45.58
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.